Relypsa announced that the Food and Drug Administration (FDA) has approved Veltassa (patiromer) for oral suspension, indicated for the treatment of hyperkalemia. The approval is based on clinical ...
The approval was based on data from the Phase 4 TOURMALINE trial which randomized 114 patients with hyperkalemia to receive Valtessa once daily with food or without food for 4 weeks The prescribing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results